Critical role of interleukin-5 in the development of a mite antigen-induced chronic bronchial asthma model

Inflammation Research

Volumn 62, Issue 10, 2013, Pages 911-917

  Shimizu, Hiroki ^a   Obase, Yasushi ^a   Katoh, Shigeki ^a   Mouri, Keiji ^a   Kobashi, Yoshihiro ^a   Oka, Mikio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Asthma; Cysteinyl leukotrienes; Dermatophagoides farinae; IL 5; IL 5 deficient mice

Indexed keywords

INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR; PEPTIDOLEUKOTRIENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE EXACERBATION; EOSINOPHILIA; EXPERIMENTAL MOUSE; FEMALE; LUNG LAVAGE; MITE; MOUSE; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT ALLERGY; SIGNAL TRANSDUCTION; TH2 CELL; WILD TYPE;

AIRWAY RESISTANCE; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; EOSINOPHILS; FEMALE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERLEUKIN-5; LEUKOCYTE COUNT; LEUKOTRIENES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-5;

EID: 84884674979     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0651-y     Document Type: Article

References (21)

1. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, Michel F-B. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033-9.
2. Bousquet JP, Jeffery K, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720-45.
3. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. 2000;105:651-63.
4. Weller PF. Human eosinophils. J Allergy Clin Immunol. 1997;100:283-7.
5. Piacentini GL, Kaliner MA. The potential roles of leukotrienes in bronchial asthma. Am Rev Respir Dis. 1991;143:S96-9.
6. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB, Montelukast Clinical Research Study Group. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 1998;158:1213-20.
7. Barnes N, Wei LX, Reiss TF, Leff JA, Shingo S, Yu C, Edelman JM. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med. 2001;95:379-86.
8. Wardlaw AJ. Molecular basis for selective eosinophil trafficking in asthma: a multistep paradigm. J Allergy Clin Immunol. 1999;104:917-26.
9. Leckie M, ten Brinke JA, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144-8.
10. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985-93.
11. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;2009(360):973-84.
12. Katoh S, Fukushima K, Matsumoto N, Matsumoto K, Abe K, Onai N, Matsushima K, Matsukura S. Accumulation of CCR4-expressing CD4+ T cells and high concentration of its ligands (TARC and MDC) in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy. 2003;58:518-23.
13. Katoh S, Fukushima K, Matsumoto N, Ehara N, Matsumoto K, Yamauchi A, Hirashima M. Accumulation of CXCR3-expressing eosinophils and increased concentration of its ligands (IP10 and Mig) in bronchoalveolar lavage fluid of patients with chronic eosinophilic pneumonia. Int Arch Allergy Immunol. 2005;137:229-35.
14. Matsumoto N, Katoh S, Mukae H, Matsuo T, Takatsu K, Matsukura S. Critical role of IL-5 in antigen-induced pulmonary eosinophilia, but not in lymphocyte activation. Arch Allergy Immunol. 2003;130:209-15.
15. Nials AT, Uddin S. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis Model Mech. 2008;1:213-20.
16. Katoh S, Kaminuma O, Hiroi T, Mori A, Ohtomo T, Maeda S, Shimizu H, Obase Y, Oka M. CD44 is critical for airway accumulation of antigen-specific Th2, but not Th1, cells induced by antigen challenge in mice. Eur J Immunol. 2011;41:3198-207.
17. Coffey M, Peters-Golden M. Extending the understanding of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2003;3:57-63.
18. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645-55.
19. Tanaka H, Kawada N, Yamada T, Kawada K, Takatsu K, Nagai H. Allergen-induced airway inflammation and bronchial responsiveness in interleukin-5 receptor alpha chain-deficient mice. Clin Exp Allergy. 2000;30:874-81.
20. Fattouh R, Al-Garawi A, Fattouh M, Arias K, Walker TD, Goncharova S, Coyle AJ, Humbles AA, Jordana M. Eosinophils are dispensable for allergic remodeling and immunity in a model of house dust mite-induced airway disease. Am J Respir Crit Care Med. 2011;183:179-88.
21. Walsh ER, Sahu N, Kearley J, Benjamin E, Kang BH, Humbles A, August A. Strain-specific requirement for eosinophils in the recruitment of T cells to the lung during the development of allergic asthma. J Exp Med. 2008;205:1285-92.